Genmab Us Patent-Cliff Exposure & CMS Drug Spending Portfolio
Genmab Us (US): 1 reconciled FDA prescription therapies, $3.8M 2024 CMS Part D & Medicaid spend, and $15,226 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | US |
| Reconciled FDA Portfolio Therapies | 1 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 0.0% |
| Primary Portfolio LOE Date | Multi-asset schedule |
| 2024 CMS Total Public Spend | $3.8M |
| 2024 Medicare Part D Spend | $1.2M |
| 2024 Medicaid Spend | $2.6M |
| California HCAI SB 17 Filings | Specialty launch notice ($15,226 intro WAC) |